however, require platelet transfusions (CRp), the frequency of such CRps was 16% in the gemtuzumab group and 0% in the ara-C regimen groups. It should be noted that although CRp may not convey the same survival advantage as CR, it does convey a survival advantage compared to patients who live a certain amount of time, eg 4-8 weeks, but achieve neither CR nor CRp.
We used statistical regression to account for differences between the gemtuzumab and ara-C groups in the distribution of important prognostic factors such as duration of first remission (CR1), age and cytogenetics. Regardless of age or cytogenetics, patients who received ara-C after a CR1 of Ͼ13-14 months were more likely to achieve CR than patients given gemtuzumab after a similar CR1. In contrast, among patients whose CR1 was less than 3-6 months CR was more likely with gemtuzumab. If CR1 was between 6 and 13 months, there was no statistical difference between ara-C and gemtuzumab, although there is a trend favoring ara-C. Repeating the analysis, but now focusing on CR + CRp, the advantage for gemtuzumab is seen in patients with CR1 of 3-10 months and for ara-C in patients with CR1 of 19 months, with no statistical differences in patients with intermediate CR1s. A similar analysis showed that, after accounting for pretreatment albumin and creatinine levels, the probability of death within the first 6 weeks of treatment was less with ara-C in patients under age 45, while there was a trend favoring GO as age increased above 65 and particularly above 75. These data support the recommended use of gemtuzumab in older patients in first relapse, but caution against its use in patients with a relatively long CR1 and in younger patients. The lack of a strong relation between CR1 and response to gemtuzumab and ara-C suggest that gemtuzumab and ara-C are qualitatively different and support their combination in clinical trials.
The possibility that gemtuzumab might produce less immediate mortality than ara-C-containing regimens led us to investigate its use in patients age 65 and older with newly diagnosed AML or high-risk MDS (Ͼ10% blasts). 4 Fifty-one patients were treated. The only exclusion criterion was that patients could not have inv (16) , t(8;21) or t (15;17) . Gemtuzumab 9 mg/m 2 days 1 + 8 or 1 + 15, with these two schedules producing equivalent results, was given +/− IL-11 (15 g/kg/d days 3-28), with assignment to +/− IL-11 made randomly. We compared gemtuzumab +/− IL-11 to IA (idarubicin 12 mg/m 2 daily × 3 + ara-C (A) 1.5 gm/m 2 daily × 3 CI), which we have found superior to regimens containing fludarabine (F), or topotecan, + A. 5 The IA/gemtuzumab +/− IL-11 comparison was limited to patients age у65 without inv 16, t(8;21) or t (15;17) . We again used statistical regression to account for possible covariate (eg cytogenetics) effects on outcome when comparing IA to gemtuzumab +/− IL-11. We also accounted for possible 'trial effects' (TE) arising because IA and gemtuzumab +/− IL-11 were not arms of a randomized trial. We did so by estimating the magnitudes of TE in previous trials involving patients with newly diagnosed AML/MDS. We Table 1 . Considering the 51 patients given gemtuzumab +/− IL-11, logistic regression indicated that cytogenetics (normal vs abnormal) and use of IL-11 were predictive of a higher CR rate. The difference in CR rate between the +/− IL-11 arms could not be attributed to an excess of CRps in the no IL-11 arm; nor were there differences in time to achieve a platelet count Ͼ100 000 among patients achieving CR on the two arms or differences in survival between the two arms. Table 2 shows Bayesian posterior probabilities that either gemtuzumab or gemtuzumab + IL-11 is superior to IA after accounting for covariates and TE. With respect to survival, extraordinarily large TE, more than five times the magnitude of those previously observed, would have to be postulated to make it likely that gemtuzumab +/− IL-11 is superior to IA. Thus, despite the lack of randomization, there is little evidence to suggest that gemtuzumab should be used rather than IA in patients age 65 and above with newly diagnosed AML/MDS. It of course remains possible that combinations of agents such as ara-C with gemtuzumab will prove useful or that the drug will find a role in post-remission therapy or as pretransplant conditioning agent. Another area of interest is in untreated acute promyelocytic leukemia (APL). APL cells are highly CD33 positive. This suggests that anti-CD33 therapy, in particular gemtuzumab, might be effective in APL, a possibility also broached by the results by Jurcic et al 6 with the 'naked' anti-CD33 monoclonal antibody, HuM195. We have combined gemtuzumab with all-trans retinoic acid (ATRA) +/− idarubicin in patients with untreated APL. 7 ATRA, 45 mg/m 2 daily, is given beginning on day 1, with gemtuzumab 9 mg/m 2 given on day 5. In patients with initial WBC 10 000-30 000 gemtuzumab begins on day 1, with idarubicin 12 mg/m 2 daily days 1-3 added if the initial WBC is Ͼ30 000. In remission Table 2 Bayesian posterior probabilities that gemtuzumab (G) or G + IL-11 is superior to IA with respect to CR or survival The lower value reflects the possibility that trial effects favor M +/− IL-11 and the higher value the possibility that trial effects favor IA.
Leukemia all patients receive ATRA 45 mg/m 2 2 weeks on, 2 weeks off, and every 5 weekly courses of gemtuzumab at a starting dose of 9 mg/m 2 , with idarubicin added only if a PCR test (at 10(−4)) fails to become negative by 4 months from CR date or reverts to positivity. PCR tests are done every 2 months with an intention to discontinue therapy after eight post-CR courses. Fourteen of the 16 patients with newly diagnosed APL seen at MD Anderson since 9/5/2000 have been placed on the above protocol. Their median age was 52 years and their median WBC count 12 300. CR has occurred in 8/9 patients whose initial WBC was Ͻ30 000 and thus received ATRA + gemtuzumab without idarubicin. A similar CR rate would likely have been obtained with ATRA alone, ie, without gemtuzumab. However, all five of the eight CR patients in whom PCR data are currently available were PCR negative either at CR date (two patients) or by 2-4 months from CR date (three patients), an occurrence that is unlikely with oral ATRA monotherapy. No patients have converted from PCR negativity to PCR positivity, although follow-up is extremely short (last negative PCR 7, 7, 6, 2 and 2 months from CR date). Median time to CR was 35 days, similar to our experience with oral ATRA + idarubicin. The eight CR patients have currently received 8, 8, 7, 3, 3, 2, 1 and 1 post-CR course of gemtuzumab. Although dose reduction has often been necessary because of myelosuppression, the courses have consistently been given at 5-week intervals. The PCR results suggest that gemtuzumab has activity in APL.
If gemtuzumab is to find a place in therapy of AML, the issue of veno-occlusive disease (VOD) of the liver must be addressed. Giles et al 8 reported a 12% incidence (14/119) of this complication among MD Anderson patients receiving gemtuzumab +/− other anti-AML agents. No predisposing factors could be identified. However, VOD has not occurred in our patients with APL and the incidence may be lower in these patients. The rate of VOD reported to the manufacturer of gemtuzumab is about 3-4%, with this rate statistically different from the MD Anderson rate. Differences in awareness of, or sensitization to, the diagnosis may underlie these differences, a possibility that will have to be addressed in prospective comparative trials.
Diphtheria toxin/GM-CSF fusion protein Another agent that targets the cell surface is the diphtheria toxin/GM-CSF fusion protein, 9 developed by Frankel and coworkers. This appears to selectively target leukemic blasts rather than normal progenitors. Presumably the high number of GM-CSF receptors on the former is responsible for the selectivity for AML blasts. A phase I study was recently reported that showed responses in some patients at the highest dose. 10 Furthermore, responses occurred in patients who had received several prior therapies. It remains to be seen whether the outcome is truly unrelated to the treatment history, and in particular, whether the patient had received ara-C. If so, it would appear plausible that this agent acts differently from ara-C. A diphtheria toxin-IL-3 fusion protein is about to move into clinical trial.
MDR reversing agents The initial group of MDR reversing agents, epitomized by cyclosporine A (CsA), interfered with hepatic metabolism of drugs such as daunorubicin. As a result, doses of these drugs had to be reduced when combined with CsA. Newer inhibitors of MDR function either have less effect on hepatic metabolism or affect other mediators of MDR. PSC 833 is an example of the first type agent. A randomized CALGB study by Baer et al 11 was conducted in older adults who were treated with ara-C, daunorubicin, and etoposide plus or minus PSC 833. The trial was stopped due to excess toxicity in the PSC 833 group. The same was true of a SWOG Leukemia pilot study (Chauncey, personal communication). Nevertheless, there is still interest in PSC 833 in patients under age 60, and the CALGB is still conducting its randomized trial in this group. It remains to be seen whether CsA might be superior to PSC 833 given results of a randomized SWOG trial showing an advantage for patients given ara-C + infusional daunorubicin + CsA. 12 Among newer agents in this category are LY-335979 which, unlike CsA and PSC 833, does not affect hepatic excretion of drugs; and VX-710 and VX-853, which inhibit both MDR1/PGP and MRP1-mediated efflux, although the prognostic significance of the latter has been questioned. 13 Farnesyl transferase inhibitors Although RAS protein mutations are relatively uncommon in AML, activation of RAS pathways can still occur even in the absence of mutation.
14 Activation of RAS pathways can play a role in maintaining AML cell proliferation. Before it can be activated, RAS has to be farnesylated, prompting interest in inhibitors of this process. The inhibitor that has received the most clinical attention to date is the Janssen compound, R115777. Between 35 and 40 relapsed, refractory AML patients were treated with this agent, and 10 patients responded. 15 It is not clear whether the same patients might not have responded to ara-C, but R115777 is particularly attractive because of this possibility. Several cycles may be needed before a response is seen. It is not clear whether there is a relationship between dose and percent inhibition of farnesyl transferase.
Angiogenesis inhibitors Several investigators have shown that microvascular density (MVD) is increased before treatment in AML and decreases following CR with conventional chemotherapy. 16 Higher levels of cellular vascular endothelial cell growth factor (VEGF) are an independent predictive factor in AML. 17 These observations have led to trials of antiangiogenesis agents in AML. The agent that has received the most attention is thalidomide. German investigators have observed CRs and instances of so-called 'hematologic improvement.' 18 Our group randomized 91 newly diagnosed patients with abnormal cytogenetics among liposomal daunorubicin + ara-C +/− thalidomide and liposomal daunorubicin + topotecan +/− thalidomide, and failed to demonstrate higher CR or survival rates with the addition of thalidomide. 19 However, it could be argued that the wrong patients were studied and that, specifically, the drug should be investigated in better prognosis patients such as those in remission. Furthermore, it is possible that only those patients with higher pretreatment levels of MVD or VEGF, or only those patients in whom thalidomide affects a decrease in MVD or VEGF, will respond. Finally, more specific angiogenesis (? more potent) inhibitors are entering clinical trial. These include the kinase inhibitors SU-5416 and SU-6668. The future of antiangiogenesis agents, like that of farnesyl transferase inhibitors, is most likely to be in combination with cytotoxic agents.
Hypomethylating agents Hypomethylation of CPG islands in the genome is a physiologic mechanism of gene inactivation that appears to be usurped by leukemia cells. 20 These cells use this mechanism to inactivate tumor suppressor genes such as P15 and P16. Decitabine is a considerably more potent inducer of hypomethylation than the related compound 5-azacitidine. Kantarjian et al 21 have demonstrated that decitabine produces CRs in blast crisis of CML. Willemze et al 22 have reported the same in relapsed AML. Because decitabine is myelosuppressive it is unclear whether the CRs are a result of myelosuppression or hypomethylation. Issa (personal communication) has demonstrated that in vitro decitabine induces demethylation of genes such as p15 and p16 at concentrations that would not be expected to produce myelosuppression in patients. This has prompted a trial at MD Anderson using low doses of decitabine (15 mg/m 2 rather than the usual 50 mg/m 2 daily) to determine if the cytotoxic and hypomethylating effects can be differentiated. The hope is that, because they will not produce hypomethylation, such low doses can be continued for several weeks thus maximizing hypomethylation. It is clear that CRs occur at the low doses used. In at least one patient, there was progressive hypomethylation of P15, while, in contrast, there was no effect on H19, which is methylated in normal individuals. Whether this will be a general finding or whether patients who respond to decitabine are those likely to respond to ara-C remains to be determined. One of the mechanisms responsible for methylation may involve the enzyme histone deacetylase. 20 This suggests future combinations of demethylating agents such as decitabine with histone deacetylase inhibitors such as phenylbutyrate and depsipeptide. Another potential direction with decitabine may be to increase expression of relevant target molecules such as CD33.
Troxacitabine Troxacitabine, an L-nucleoside analog, is the first drug of its type to show anticancer activity. In a phase I study, Giles et al 23 demonstrated CRs in patients with relapsed AML or CML in blastic phase, although it is too early to speak of a response rate per se or whether the patients likely to respond to troxacitabine are those likely to respond to ara-C. Interest in the drug would likely be greater if such were not the case. With this thought in mind, our group is currently randomizing untreated patients with cytogenetic abnormalities (and hence unlikely to have remission durations Ͼ6-12 months when given ara-C-containing therapy) among troxacitabine + ara-C, troxacitabine + idarubicin, or idarubicin + ara-C.
Conclusion Traditionally, new putative anti-AML agents are first investigated in patients with advanced stage disease, eg, multiply relapsed. If there is little demonstrable efficacy, there is reluctance to use the drug in patients with more favorable prognoses. It is plausible, however, that the better prognosis patients might respond although the worst prognosis patients did not. Thus it may be advisable, once optimum doses have been established in the worst prognosis patients, to routinely investigate the agents in better prognosis patients, including those in first remission, but in whom CR1 is expected to be transient. This problem might be obviated were an empirical definition of hematologic improvement following treatment with new agents established in worse prognosis patients. Such a definition, while not meeting criteria for CR or CRp in such patients, might predict such a response in better prognosis patients. Finally, it is important to keep in mind that there are a tremendous number of permutations and combinations with these treatments. There is a real need for pilot studies and for different statistical thinking. Investigators will need to move away from the P = 0.05 significance mentality and base their statistical thinking on other approaches. 
